Articles about "drug discovery"

MIT researchers are employing artificial intelligence to accelerate the identification and synthesis of novel drug candidates by integrating chemical knowledge into computational models. The approach, led by Associate Professor Connor Coley, combines machine learning with an understanding of chemical principles, improving prediction accuracy and aiding pharmaceutical development.

Two AI-powered assistants developed by Google and FutureHouse have successfully aided scientists with drug retargeting tasks, according to new studies published in Nature. These systems help researchers analyze extensive biological data and generate hypotheses, streamlining the process of identifying potential new uses for existing drugs. Both platforms highlight the growing role of artificial intelligence in accelerating scientific discovery.

SandboxAQ has made its drug discovery artificial intelligence models available through Claude, a widely used conversational AI system. This integration aims to make advanced computational drug research tools accessible to users without specialized technical backgrounds.

Isomorphic Labs has announced a $2.1 billion Series B funding round to accelerate its AI-driven drug discovery initiatives. The financing, led by Thrive Capital and supported by Alphabet and other major investors, will be used to enhance the company’s drug design platform and expand its research into treatments for cancer and immune disorders.

OpenAI has introduced GPT-Rosalind, a specialized AI model designed for the challenges of life sciences research. The model aims to assist researchers in integrating fragmented biological data and generating refined scientific hypotheses, with early performance benchmarks indicating better results than previous models for complex research workflows.

Accel has committed $5 billion in new funding for technology startups, highlighting ongoing interest in artificial intelligence. Helical, an AI-powered drug discovery firm, closed a $10 million round, underlining the sector's momentum. Both moves indicate sustained investment in innovative AI-driven business models.

OpenAI has introduced GPT-Rosalind, a large language model tailored for biology research workflows. The model is trained on key biological processes and integrates access to major biological databases, supporting researchers in data analysis and hypothesis generation.

OpenProtein.AI is making advanced AI-driven protein design tools available to biologists through a user-friendly, no-code platform. The company is facilitating faster drug development by allowing scientists to design, predict, and optimize proteins without requiring machine learning expertise.

Helical, a biotech firm focusing on AI-driven pharmaceutical research, has raised $10 million in a seed funding round led by Redalpine. The company’s virtual AI lab aims to streamline drug discovery by integrating computational predictions with biological validation. The funds will support deeper collaborations with pharmaceutical companies and further platform development.

Researchers at MIT are developing improved machine learning methods to model protein structures, with potential impacts in medicine and agriculture. Sergei Kotelnikov, a computational biologist, employs neural networks and physics-driven approaches to enhance biomolecular simulations. These advances could accelerate drug discovery and shed light on the fundamental processes underlying life.